Lymphoma Follow-up
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This follow-up protocol is designed to evaluate participants who have previously been lymphoma patients treated on approved clinical studies of the National Institutes of Health.
| Condition |
|---|
|
Lymphoma |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Lymphoma Follow-up Protocol |
- Long-term survival following treatment for lymphoma [ Time Frame: Annually ] [ Designated as safety issue: No ]
- Long-term toxicity possibly attributable to lymphoma or treatment for lymphoma [ Time Frame: Annually ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Blood serum
| Estimated Enrollment: | 800 |
| Study Start Date: | October 2003 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
The intent of this protocol is to accrue up to 800 volunteers who are interested in participating in NIA research studies as part of follow-up for previous cancer treatment at NIH. Participants will be asked to answer questions regarding their general health status, diagnoses, and admissions to hospital, and to provide possible documentation. They may be asked to come to the NIA Clinical Research Unit at Harbor Hospital to participate in a follow-up evaluation. They will have the opportunity to obtain additional information about studies in which they may wish to participate and to discuss eligibility issues with NIA staff members. Any identified clinical problems in need of care will also be discussed. Volunteers may be referred, with their permission, to their private medical doctor for follow-up. They may be re-evaluated within a year for further follow-up.
The follow-up evaluation may include history and physical, blood and urine tests, questionnaire, MRI or CT.
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients, previously entered on NIH study who may be eligible if they have rare, unusual, interesting or unknown conditions that require diagnosis
Inclusion Criteria:
- Previously treated on an approved NCI/NIH protocols
- Willing and able to provide informed consent for current NIA protocol
- Rare, unusual, interesting or unknown condition that requires diagnosis
Exclusion Criteria:
- Does not meet the criteria of any previously-approved NIH Protocol.
Contacts and Locations| United States, Maryland | |
| NIA Clinical Research Unit | |
| Baltimore, Maryland, United States, 21225 | |
| Principal Investigator: | Patricia L. Duffey, RN | National Institute on Aging (NIA) |
More Information
No publications provided
| Responsible Party: | National Institutes of Health Clinical Center (CC) ( National Institute on Aging (NIA) ) |
| ClinicalTrials.gov Identifier: | NCT00744120 History of Changes |
| Other Study ID Numbers: | AG0108; 03-AG-N337 |
| Study First Received: | August 28, 2008 |
| Last Updated: | April 25, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institutes of Health Clinical Center (CC):
|
cancer |
Additional relevant MeSH terms:
|
Lymphoma Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders |
Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on May 21, 2013